SOUTH SAN FRANCISCO, Calif., April 21, 2016 (GLOBE NEWSWIRE) — Calithera Biosciences, Inc. (Nasdaq:CALA) a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, today announced that clinical data for its lead drug candidate CB-839, the Company’s novel, orally bioavailable glutaminase inhibitor, will be presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO), which is being held from June 3 to June 7, 2016 in Chicago, Illinois. Clinical results to be presented include data from Calithera’s Phase I combination trial in solid tumors. Calithera will hold an investor and analyst briefing Monday, June 6, 2016, in Chicago, Illinois at 6:30 p.m. CT. The meeting will be webcast live and available for replay for 30 days at www.calithera.com under the Investors section.
Phase 1 study of CB-839, a small molecule inhibitor of glutaminase in combination with paclitaxel in patients with triple negative breast cancer.
Abstract #1011
Presenter: Angela DeMichele, MD, MSCE, University of Pennsylvania
Date: June 5, 2016
Poster Display: 8:00 a.m. – 11:30 a.m. CT, Hall A, Board #116, Breast Cancer—Triple-Negative/ Cytotoxics/ Local Therapy
Poster Discussion: 4:45 p.m. – 6:00 p.m. CT, Hall D2
Phase 1 study of CB-839, a small molecule inhibitor of glutaminase, alone and in combination with everolimus in patients with renal cell cancer.
Abstract #4568
Presenter: Funda Meric-Benstam, MD, University of Texas MD Anderson Cancer Center
Date: June 6, 2016
Poster Display: 1:00 p.m. – 4:30 p.m. CT, Hall A, Board #190, Genitourinary (Nonprostate)
About Calithera Biosciences
Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Calithera’s lead product candidate, CB-839, is currently being evaluated in three Phase 1 clinical trials in solid and hematological cancers. CB-1158 is a first-in-class immuno-oncology metabolic checkpoint inhibitor targeting arginase, a critical immunosuppressive enzyme responsible for T-cell suppression by myeloid-derived suppressor cells. Arginase depletes arginine, a nutrient that is critical for the activation, growth and survival of the body’s cancer-fighting immune cells, known as cytotoxic T-cells. Calithera is headquartered in South San Francisco, California. For more information about Calithera, please visit www.calithera.com.
CONTACT: CONTACT: Jennifer McNealey ir@Calithera.com 650-870-1071
